| The Association of Microbiota Composition With cGVHD After Allo-HSCT (NCT05355675) | First Affiliated Hospital of Zhejiang University | 2022-05-01 |
| Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial (NCT05236062) | Dana-Farber Cancer Institute | 2022-04-14 |
| Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host Disease (NCT05348096) | Hospital Universitario Dr. Jose E. Gonzalez | 2022-04-01 |
| Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 (NCT05305989) | Kadmon, a Sanofi Company | 2022-02-23 |
| Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease (NCT05121142) | Children's Hospital Medical Center, Cincinnati | 2021-10-27 |
| A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease (NCT04944043) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-06-25 |
| A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib (NCT04640025) | Incyte Corporation | 2021-03-10 |
| A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) (NCT04710576) | Syndax Pharmaceuticals | 2021-03-04 |
| Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD (NCT04446182) | University of Utah | 2021-01-29 |
| MSC for Treatment of cGVHD After Allo-HSCT (NCT04692376) | Nanfang Hospital, Southern Medical University | 2021-01-10 |
| Dexamethasone Solution and Dexamethasone in Mucolox™ (NCT04540133) | University of California, San Francisco | 2020-12-26 |
| Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study (NCT04372524) | University of British Columbia | 2020-11-15 |
| ATG Plus PTCy vs ATG for CGVHD Prophylaxis (NCT04202835) | McMaster University | 2020-10-14 |
| Predicting the Quality of Response to Specific Treatments in Patients With cGVHD, PQRST Study (NCT04431479) | Fred Hutchinson Cancer Center | 2020-06-29 |
| A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) (NCT04200365) | SCRI Development Innovations, LLC | 2020-06-05 |
| Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease (NCT04212416) | City of Hope Medical Center | 2020-05-12 |
| Anlotinib Treatment in Steroid Depenent/Refractory cGVHD (NCT04232397) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2020-04-10 |
| Glasdegib for Chronic Graft-Versus-Host Disease (NCT04111497) | Fred Hutchinson Cancer Center | 2019-12-03 |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) (NCT04716075) | Polish Lymphoma Research Group | 2019-08-19 |
| Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT (NCT03689894) | Dartmouth-Hitchcock Medical Center | 2019-04-11 |
| GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (NCT03584516) | Incyte Corporation | 2019-01-17 |
| Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD) (NCT03790332) | Pharmacyclics LLC. | 2018-11-19 |
| A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD (NCT03604692) | Syndax Pharmaceuticals | 2018-11-01 |
| Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy (NCT03640481) | Kadmon, a Sanofi Company | 2018-10-11 |
| Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies (NCT03557749) | Masonic Cancer Center, University of Minnesota | 2018-09-21 |
| Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease (NCT03483675) | Fred Hutchinson Cancer Center | 2018-06-06 |
| A Prospective Observational Study for Evaluating CGVHD (NCT02991846) | Gruppo Italiano Trapianto di Midollo Osseo | 2017-09-01 |
| A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT (NCT03190733) | Zhujiang Hospital | 2017-08-30 |
| Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD) (NCT02959944) | Pharmacyclics LLC. | 2017-05-11 |
| Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide (NCT02966301) | Medsenic | 2016-12-01 |
| Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation (NCT02759731) | National Cancer Institute (NCI) | 2016-11-01 |
| Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD (NCT02461134) | Actelion | 2016-09-29 |
| Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease (NCT04189432) | SCM Lifescience Co., LTD. | 2016-09-28 |
| Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis (NCT03839069) | National Taiwan University Hospital | 2016-09-01 |
| Multiple Donor Treg DLI for Severe Refractory Chronic GVHD (NCT02749084) | Mario Arpinati | 2016-08-03 |
| Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD) (NCT02701634) | Gilead Sciences | 2016-05-27 |
| Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation (NCT02669251) | National Cancer Institute (NCI) | 2016-04-28 |
| Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease (NCT02513498) | Fred Hutchinson Cancer Center | 2015-12-08 |
| Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease (NCT02491359) | Fred Hutchinson Cancer Center | 2015-11-12 |
| Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease (NCT02337517) | National Cancer Institute (NCI) | 2015-09-08 |
| Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease (NCT02611180) | Washington University School of Medicine | 2015-04-30 |
| A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD (NCT02340676) | Dana-Farber Cancer Institute | 2015-02-01 |
| BMT Autologous MSCs for GvHD (NCT02359929) | Emory University | 2015-01-01 |
| Evaluation of the Diagnostic Value of PET (18F-FDG) in Chronic Graft Versus Host Disease (cGVH) (NCT02352064) | University Hospital, Caen | 2015-01-01 |
| An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease (NCT02123966) | Dana-Farber Cancer Institute | 2014-07-01 |
| Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) (NCT01954979) | Beth Israel Deaconess Medical Center | 2014-03-27 |
| Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD (NCT02411474) | Yonsei University | 2014-03-01 |
| Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (NCT02040623) | Rigel Pharmaceuticals | 2014-03-01 |
| Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease (NCT01937468) | Dana-Farber Cancer Institute | 2013-11-01 |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) (NCT01804686) | Janssen Research & Development, LLC | 2013-09-09 |
| Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children (NCT01898377) | Seoul National University Hospital | 2013-08-01 |
| Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD) (NCT01903473) | University of Liege | 2013-07-01 |
| Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (NCT01862965) | Universitätsklinikum Hamburg-Eppendorf | 2013-03-06 |
| Microvascular and Fibrosis Imaging Study (NCT01758250) | Duke University | 2013-02-01 |
| Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease (NCT01765660) | Nanfang Hospital, Southern Medical University | 2013-01-01 |
| Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease (NCT01680965) | H. Lee Moffitt Cancer Center and Research Institute | 2012-11-14 |
| Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease (NCT01526850) | Chinese Academy of Medical Sciences | 2012-02-01 |
| Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD) (NCT01380535) | Mallinckrodt | 2011-11-01 |
| Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD (NCT01810718) | Gruppo Italiano Trapianto di Midollo Osseo | 2011-11-01 |
| Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease (NCT01366092) | Dana-Farber Cancer Institute | 2011-07-01 |
| Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD) (NCT01161628) | Northside Hospital, Inc. | 2011-04-01 |
| Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD) (NCT01964625) | University of Rochester | 2010-11-01 |
| Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease (NCT01226420) | Dana-Farber Cancer Institute | 2010-10-01 |
| Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD) (NCT01158105) | Baylor Research Institute | 2010-06-01 |
| Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell. (NCT01956903) | Grupo Espanol de trasplantes hematopoyeticos y terapia celular | 2010-01-01 |
| Development and Validation of a Symptom Scale for Children With Chronic Graft-versus-Host Disease (NCT01036958) | National Cancer Institute (NCI) | 2009-11-25 |
| Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease (NCT00815919) | Dana-Farber Cancer Institute | 2008-12-01 |
| Montelukast to Treat Bronchiolitis Obliterans (NCT00656058) | National Cancer Institute (NCI) | 2008-06-17 |
| Improving Outcomes Assessment in Chronic GVHD (NCT00637689) | Fred Hutchinson Cancer Center | 2007-09-01 |
| Treatment of Chronic GVHD of Liver or Lungs by ECP (NCT00271869) | Medical University of Vienna | 2005-12-01 |
| A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease (NCT01028313) | SCRI Development Innovations, LLC | |